BioCentury
ARTICLE | Clinical News

Regulus falls on Phase I HCV data

February 10, 2015 1:50 AM UTC

Regulus Therapeutics Inc. (NASDAQ:RGLS) fell $1.22 to $15.64 on Monday after reporting data from a Phase I study of RG-101 to treat HCV, including follow-up results from a cohort receiving a single 2 mg/kg dose and top-line results from a cohort receiving a single 4 mg/kg dose.

Regulus said four (29%) of 14 treated patients in the 2 mg/kg cohort were classified as "target not detected" at day 85. Two (14%) of the 14 whose HCV RNA levels were below the limit of quantification at day 57 relapsed shortly afterward. ...